基于PDB数据的国家药品集中采购政策对调血脂药品市场格局的影响研究  

Research on the Impact of National Drug Centralized Procurement Policy on the Structure of Lipid-Regulating Drugs Analysis Based on PDB Data

作　　者：王文睿 谢金平 邵蓉[2,3] WANG Wen-rui;XIE Jin-ping;SHAO Rong(Institute of Regulatory Science for Medical Products,China Pharmaceutical University,Nanjing,211198,China;不详)

机构地区：[1]中国药科大学药品监管科学研究院,南京211198 [2]中国药科大学国家药物政策与医药产业经济研究中心,南京211198 [3]国家药品监督管理局药品监管创新与评价重点实验室,南京211198

出　　处：《中国卫生经济》2023年第3期1-5,共5页Chinese Health Economics

基　　金：江苏省教育厅2022年度江苏高校哲学社会科学研究一般项目(2022SJYB0075)。

摘　　要：目的:研究国家药品集中采购政策执行前后调血脂药品市场变化,分析国家药品集中采购政策实施效果。方法:基于中国医药工业信息中心药物综合数据库2015—2021年样本医院调血脂药品销售数据,对国家药品集中采购政策实施前后调血脂类药品总体销售额、集采与非集采他汀品种的销量及销售额占比进行对比分析。同时,也对不同品种集采原研药厂家、过评厂家与未过评厂家的销量、销售额占比进行分析。结果:国家药品集中采购政策实施后,调血脂药品市场呈现出销售额下降的趋势;具体集采品种在销量、销售额表现上呈现一定的差异;集采原研品种在销量占比下降的同时,销售额占比小幅增长。结论:国家药品集中采购政策在节省药品费用方面效果显著,但也存在未真正显现“专利悬崖”现象及同类可替代药品销售额上涨等问题。建议在开展国家药品集中采购政策时,应当合理遴选集采品种,加强对同类可替代药品及未过评仿制药使用的监测。Objective:To analyze the effects of national drug centralized procurement policy to research the market change of lipid-regulating drugs before and after the implementation of this policy.Methods:Based on the lipid-regulating drugs sales data from 2015 to 2021 in sample hospitals from Pharmaceutical Database of China National Pharmaceutical Industry Information Center,it makes comparative analysis on the effect of sales of lipid-regulating drugs,the percentage of sales volume and sales of medicine that belong to or not belong to national drug centralized procurement.Besides,the percentage of sales volume and sales of the original drug,generic medicine passing consistency evaluation and generic medicine failing consistency evaluation are also analyzed.Results:After implementation of national drug centralized procurement policy,the sales of lipid-regulating drugs decreased.The different medicines of national drug centralized procurement had different phenomenon in sales volume and sales.The sales of original drug that belong to the national drug centralized procurement increased,while the sales volume decreased.Conclusion:The policy has significant effect in saving drug cost,while there are still problems such as the patent cliff still hasn’t appeared,and the sales of alternative medicines have raised.It suggests that implementation of national drug centralized procurement policy should reasonably select collection varieties,while strengthening the monitoring of alternative medicines and generic medicine failing consistency evaluation.

关 键 词：国家药品集中采购政策 调血脂药品 实施效果 

分 类 号：R1-9[医药卫生—公共卫生与预防医学] R190